Similar articles

• Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.

  Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Rühl A, Irngartinger G, Stremmel W, Rudi J. Dimitrakopoulou-Strauss A, et al. J Nucl Med. 2004 Sep;45(9):1480-7. J Nucl Med. 2004. PMID: 15347714 Clinical Trial.
• 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases.

  Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, Hricak H, Klimstra D, Fong Y. Riedl CC, et al. J Nucl Med. 2007 May;48(5):771-5. doi: 10.2967/jnumed.106.037291. J Nucl Med. 2007. PMID: 17475966 Clinical Trial.
• Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

  Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, Paone G, Talbot JN, Rahmouni A, Meignan M. Lin C, et al. J Nucl Med. 2007 Oct;48(10):1626-32. doi: 10.2967/jnumed.107.042093. Epub 2007 Sep 14. J Nucl Med. 2007. PMID: 17873129
• 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.

  Kostakoglu L, Goldsmith SJ. Kostakoglu L, et al. J Nucl Med. 2003 Feb;44(2):224-39. J Nucl Med. 2003. PMID: 12571214 Review.
• The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.

  Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. Wiering B, et al. Cancer. 2005 Dec 15;104(12):2658-70. doi: 10.1002/cncr.21569. Cancer. 2005. PMID: 16315241 Review.